Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06068075 · ClinicalTrials.gov registry record · NA

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

A NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
340
Enrollment target
15
Study locations

NCT06068075 is a NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 340 participants, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (251% higher). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06068075, a NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
340 participants
Enrollment target
15
Study locations

Study Summary

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

Conditions Studied

Ewing Sarcoma Peripheral Primitive Neuroectodermal Tumor Ewing Sarcoma of Bone High-grade Osteosarcoma Ewing Sarcoma of Soft Tissue Peripheral Primitive Neuroectodermal Tumor of Bone Peripheral Primitive Neuroectodermal Tumor of Soft Tissue

Interventions

  • OTHER FoundationOne Liquid CDx

Study Locations (15)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Boston Children's Hospital - Boston
  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Nationwide Children's Hospital - Columbus

California

  • Childrens Hospital Los Angeles - Los Angeles

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Minnesota

  • Children's Hospital's and Clinics of Minnesota - Minneapolis

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Rhode Island

  • Lifespan / Rhode Island Hospital - Providence

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 340 participants
Start Date 2018-05-08
Est. Completion 2027-01-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06068075

The ClinicalTrials.gov registry entry for NCT06068075 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (251% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Ewing Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne Liquid CDx is the first listed.

NCT06068075 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06068075 about?

NCT06068075 is a clinical study titled "Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD". This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

What is the current status of trial NCT06068075?

This trial is currently recruiting. It is a NA study. The enrollment target is 340 participants. The study started on 2018-05-08. Estimated completion is 2027-01-01.

What conditions does trial NCT06068075 study?

This clinical trial studies the following conditions: Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Ewing Sarcoma of Bone, High-grade Osteosarcoma, Ewing Sarcoma of Soft Tissue.

What interventions are being tested in trial NCT06068075?

The interventions under investigation include: FoundationOne Liquid CDx (OTHER).

Who is sponsoring clinical trial NCT06068075?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06068075 being conducted?

This trial has 15 study locations across California, Georgia, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ewing Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ewing Sarcoma

All registered trials for this condition

Peripheral Primitive Neuroectodermal Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.